With the realization that CPT analogs such as topotecan and Irinotecan (CPTs) displayed anti-cancer activity during clinical trials in the early 1990s[12], there was growing appreciation that, in addition to its role as the sole target for CPTs, Top1 also mediated the cytotoxic effects of diverse treatments. Here, TOP1 is linked to cancer.